and schizophrenia. He has authored over 90 peer-reviewed publications and received the Distinguished Investigator Award from the Academy of Radiology Research. Dr. Huang's deep expertise in brain ...

Optical illusions are great fun, and they fool virtually everyone. But have you ever wondered if you could train yourself to unsee these illusions? Our latest research suggests that you can. Optical ...

—For Canadian patients at risk for schizophrenia, the legalization of cannabis may not have been a good thing. The rate of cannabis use disorder associated with schizophrenia nearly tripled ...

"Our findings show that the schizophrenia diagnosis in narcoleptic patients is a phenomenon that does not occur only by chance but also having NT1 can be considered as a risk factor for developing ...

Schizophrenia is a mental health condition that demands vigilance. Even with a good response to initial treatment, schizophrenia symptoms often return. A return or worsening of symptoms following ...

The novel PDE10A inhibitor CPL'36 offers a new mechanism of action and is both safe and effective for acute exacerbations of schizophrenia, new research suggests.

Schizophrenia managed to steal a few things from Susan Tormoen, but not her artistic talent. These days you can find the 89-year-old painting at Cottonwood Center for the Arts, where she’s had a ...

Antipsychotic medication and psychotherapy are the first-line treatments for schizophrenia, but there are many complementary and integrative therapies that may also be beneficial for improving ...

Though the DSM-5 no longer recognizes schizophrenia subtypes as separate diagnostic categories, the five classical subtypes are paranoid, hebephrenic, undifferentiated, residual, and catatonic.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti ™) for the treatment of acute bipolar I disorder and schizophrenia.